Prof Rob Pieters talks to ecancer at the ALL Assembly 2018 Meeting in Amsterdam about the management of MLL-rearranged ALL.
Prof Pieters discusses what these rearrangements mean for prognosis and also for screening and the treatment selection.
He goes on to talk about the new targets in therapy: demethylating agents and HDAC inhibitors.
ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.